INTRODUCTION
============

*Streptococcus pneumonia* colonizes the human nasopharynx and is the leading causative agent of otitis media, respiratory infection, bacteremia, and meningitis, leading to high morbidity and mortality worldwide \[[@B1], [@B2]\]. In recent years, treatment for *S. pneumoniae* has become difficult owing to the global rise in the prevalence of antibiotic resistance, particularly against first-line antibiotics such as erythromycin and penicillin \[[@B3]\].

Macrolide resistance in *S. pneumoniae* is mediated by 2 major mechanisms: ribosomal modification by 23S rRNA methylation \[[@B4]\] and active drug efflux \[[@B5]\] encoded by *erm*(B) and *mef* genes, respectively. The macrolide efflux pump proteins belong to the major facilitator superfamily of transporters, and several mef genes have also been described in other microbial species \[[@B6]\].

M phenotype, which is mediated by mef genes, was first demonstrated in *S. pneumonia* and *S. pyogenes*. The 2 variants, *mef*(A) and *mef*(E), are 90% similar and were long regarded as a single gene class because they were not distinguishable by PCR \[[@B7], [@B8]\].

The genetic elements for the two variants are carried on different but related elements \[[@B7]\]. The *mef*(A) gene is carried on the defective transposon Tn*1207.1* or the closely related Tn*1207.3* and *mef*(E) on the \"macrolide efflux genetic assembly\" (*mega*) element. Other mobile genetic elements have also been described, such as the Tn*916* family, which contains composite elements, such as *tet*M plus mega (Tn*2009*), and *tet*M, *erm*(B), and *mega* (Tn*2010*) \[[@B3]\].

Distribution of these transposons and the genes carried by them vary in different geographic regions \[[@B9]\], thereby providing an indication towards the origin of antibiotic-resistant strains of *S. pneumoniae*. It is, therefore, important to understand the distribution of macrolide resistance in different countries. In addition, analysis of the molecular genetics of erythromycin resistance by including the types of transposons and their resistance-conferring genes in clinical and normal flora pneumococci isolates with M phenotype would add to our present knowledge of the molecular epidemiology of *S. pneumoniae*.

METHODS
=======

1. Specimen collection
----------------------

The isolates were collected from patients admitted to the city hospitals and private laboratories in Tehran, Iran. The studies were carried out over a period of 24 months, from 2011 to 2013. Only one isolate per patient was included in the study. Nasopharynx normal flora isolates were collected from healthy people. Patients who had any antibiotic treatment in the last 6 months were excluded from the study. A consent form was filled by the participants.

2. Species identification
-------------------------

Specimens were streaked on 5% sheep blood agar plate (Merck KGaA, Darmstadt, Germany) and were incubated for 24-48 hr at 37℃ in a candle jar. Standard microbiological techniques using typical colonial appearance, hemolysis, Gram staining, bile solubility, and susceptibility to optochin (1 µg) discs were performed for species identification. *S. pneumonia* ATCC 49619 was used for quality control. The final identification was confirmed by PCR using species-specific primers for amplification of *lyt*A gene. The primer sets used were *lyt*A-F: CGGACTAC GCCTTTATATCG and *lyt*A-R: GTTTCAATCGTCAAGCCGTT \[[@B10]\].

3. Macrolide resistance phenotypes
----------------------------------

Isolates were primarily identified as macrolide-lincosamide-streptogramin~B~ (MLS~B~)-resistant phenotypes by the double-disc diffusion method using erythromycin (15 µg) (Mast Diagnostics Ltd, Bootle, Merseyside, UK) and clindamycin (2 µg) (Mast Diagnostics Ltd) standards discs. Constitutive, inducible, or M phenotypes were determined by placing the clindamycin disc adjacent to erythromycin. After 24-hr incubation, flattened colonies around the clindamycin zone and in the area between the two discs (D zone) had an inducible MLS~B~ (iMLS~B~) phenotype, whereas the absence of blunting indicated the presence of the constitutive MLS~B~ (cMLS~B~) phenotype. The M phenotype was characterized by clindamycin susceptibility with no blunting of the inhibition zone around the clindamycin disc \[[@B11]\].

4. Macrolide resistance genotype
--------------------------------

DNA extraction of pneumococcal isolates was done with peqGOLD Bacterial DNA Kit (peQlab, Erlangen, Germany). The erythromycin resistance and genetic elements genes were detected by PCR with two sets of primers specific for *erm*(B), *mef*(A/E), and *tet*M ([Table 1](#T1){ref-type="table"}) \[[@B12]\]. The PCR amplicons were produced by an initial cycle at 95℃ for 10 min, followed by 30 cycles of denaturation at 94℃ for 30 sec, annealing at 57℃ for 30 sec, and extension at 72℃ for 30 sec with a final extension at 72℃ for 5 min.

PCR-based confirmation for the presence of *mef* gene was performed with a set of primer pairs ([Table 1](#T1){ref-type="table"}) that also enabled recognition of the type of genetic organization of the transposon. The PCR program for *int* and *xis* genes were as follows: an initial cycle at 95℃ for 10 min, followed by 30 cycles of denaturation at 94℃ for 30 sec, annealing at 52℃ for 30 sec, and extension at 72℃ for 30 sec with a final extension at 72℃ for 5 min.

5. Determination of antibiotic susceptibility
---------------------------------------------

Isolates primarily identified as pneumococci with M phenotype were subsequently tested for resistance against tetracycline (30 µg), oxacillin (1 µg), clindamycin (2 µg), cotrimoxazole (1.25/23.75 µg), vancomycin (30 µg), and chloramphenicol (30 µg) (Mast Diagnostics Ltd) by employing the disc diffusion agar method.

Minimum inhibitory concentrations (MICs) of erythromycin were determined by the Etest (Liofilchem, Via Scozia, Italy) method on Mueller-Hinton agar with 5% defibrinated sheep blood according to the manufacturer\'s instructions. All plates were incubated at 37℃ for 20 hr. The MICs for penicillin for all isolates with the M phenotype were also determined by the Etest method. MIC results were interpreted according to the guidelines of the Clinical and Laboratory Standard Institute \[[@B13]\].

6. BOX-PCR
----------

All pneumococcal isolates with the M phenotype were typed by using BOX-PCR with the *box*A 5\'-CTACGGCAAGGCGACGCTGACG-3\'primer \[[@B14]\].

PCR for amplification was performed under the following conditions: pre-denaturation at 95℃ for 7 min, 30 cycles each of denaturation at 90℃ for 30 sec, primer annealing at 48℃ for 1 min, chain extension at 65℃ for 8 min, and a single cycle extension at 65℃ for 16 min. After amplification, products were elecrophoresed in a 1% agarose gel with 0.5×Tris-borate-EDTA at 100 V for 3 hr. The gel was stained with ethidium bromide (1 mg/mL) and viewed with UV light. Banding patterns that differed from each other by more than three bands were examined visually.

RESULTS
=======

1. Bacterial isolates
---------------------

In our study, 92 clinical and 94 normal flora isolates were identified as pneumococci. Antibiotic susceptibility results for erythromycin revealed that 43 (46%) from clinical and 45 (49%) from normal flora isolates were resistant to erythromycin. Clinical isolates were obtained from blood (15), cerebrospinal fluid (6), lung secretions (9), eyes (8), sinuses (1), trachea (1), and ears (3).

2. Phenotypic and genotypic detection of the M phenotype
--------------------------------------------------------

The double-disc diffusion test with erythromycin and clindamycin for the 88 test strains revealed that 74 (84%) indicated the cMLS~B~ phenotype, and 14 (16%) were assigned to the M phenotype. These findings, together with the ranges of MICs of erythromycin, are summarized in [Table 2](#T2){ref-type="table"}. Amongst the isolates, *erm*(B) gene alone was detected in 39 (44%) and *mef*(A/E) in14 (16%) isolates, while 35 (40%) isolates harbored both *erm*(B) and *mef*(A/E) simultaneously as shown in [Table 2](#T2){ref-type="table"}. The association of *tet*M and *mef* gene was found in 100% of isolates with the M phenotype.

To gain further insights into the 14 strains with the M phenotype carrying the *mef*(A/E) genetic elements, we investigated the presence of two genes, *xis* and *int*, associated with Tn*2009*. The results revealed that all isolates carrying the *mef* gene were also positive for *xis* and *int*, thus exhibiting association with Tn*2009* ([Table 3](#T3){ref-type="table"}).

3. Antibiotic resistance
------------------------

All the resistant isolates with M phenotype were resistant to tetracycline (100%) and cotrimoxazole (100%), and 42% were also resistant to chloramphenicol, while they were all found to be susceptible to clindamycin and vancomycin. The erythromycin MIC for 84% of isolates with cMLS~B~ phenotype was ≥256 µg/mL. The MIC for all of isolates with the M phenotype was 1.5-16 µg/mL ([Table 2](#T2){ref-type="table"}). Furthermore, results obtained from MIC for penicillin indicated only one resistant isolate (≥2 µg/mL), 3 isolates with high susceptibility (\<0.1 µg/mL), and the remaining within intermediate susceptibility (0.1-1.5 µg/mL).

4. Typing with BOX PCR
----------------------

According to the BOX PCR typing method, the erythromycin-resistant strains with M phenotype belonged to 3 common types with 10 isolates and 4 single types ([Table 3](#T3){ref-type="table"}). All normal flora samples were divided in two common types, whilst the clinical samples included one common type and four single types.

DISCUSSION
==========

There has been an increase in the numbers of erythromycin-resistant *S. pneumoniae* strains worldwide \[[@B3]\]. The previous year also witnessed a worldwide increase in the prevalence of efflux mechanisms (M phenotype) amongst the *S. pneumoniae* strains \[[@B15]\]. In line with this, our results show a high prevalence of resistance to macrolides (47%), and the M phenotype was found in 16% of the isolates, all of which carried *mef*(A/E). These values are much higher than that determined in other studies, 9.1% in Spain and 3.1% in France \[[@B9], [@B16]\] reporting lower prevalence of *mef*(A/E) among macrolide-resistant isolates. Our results are also consistent with the studies on pneumococcal macrolide resistance, which show that it is more prevalent in the United States and Canada, with a higher rate of M phenotype and *mef*(A/E) genotype compared with European countries \[[@B16]\].

Almost 40% of the pneumococcal isolates obtained from Korea and South Africa have been reported to carry *erm*(B) and *mef*(A/E) genes \[[@B17], [@B18]\]. Moreover, other countries have also reported, to lesser extent, simultaneous presence of the two genes \[[@B3], [@B7], [@B18], [@B19]\]. Overall, all the reports suggest an emergence of resistant pneumococci *erm*(B) and *mef*(E) genes worldwide.

As expected, the present results showed that the isolates with *erm*(B) gene alone or with *mef* were highly resistant to erythromycin. On the other hand, the strains with *mef*(A/E) alone showed low-level resistance to erythromycin, which is the typical characteristic of strains with the M phenotype \[[@B18], [@B20]\].

Here, we showed that the isolates with M phenotype were associated with high rates of chloramphenicol, cotrimoxazole, and tetracycline resistance. In addition, penicillin remains a therapeutic choice for all of the isolates (10 intermediate and 1 resistant), which were detected as susceptible, except for three penicillin-resistant isolates. The results obtained are consistent with other reports suggesting concomitant resistance to erythromycin and other antibiotics with therapeutic options \[[@B20], [@B21]\]. Furthermore, we observed that all isolates with M phenotype were also resistant to tetracycline. The resistance to tetracycline has frequently been associated with erythromycin \[[@B7]\].

The high resistance rate to tetracycline might also be due to the presence of Tn*2009* encoding genes conferring tetracycline and erythromycin resistance. All of the isolates with *mef*(A/E) were positive for *int* and *xis* by PCR. This combination of genes is characteristic of Tn*2009*, which is a Tn*916*-related transposon. Cochetti et al. \[[@B8]\] have also reported the mega element as a major element carrying *mef*(A/E) gene. This transposon was detected in other studies as the genetic element conferring macrolide resistance in pneumococcal isolates \[[@B9], [@B22]\].

Using BOX PCR typing, we showed the pneumococci with M phenotype in clinical isolates to be polyclonal, whereas normal flora isolates were clonally related. As reported earlier \[[@B16]\], the emergence of efflux mechanism of macrolide resistance is not clonally related in clinical isolates. They can, however, be transferred clonally.

In conclusion, the rate of macrolide resistance in our *S. pneumoniae* collection was high. Although the cMLS~B~ phenotype predominates macrolide resistance in Iran, the M phenotype, appears to be emerging as an important factor in erythromycin-resistant pneumococci. A majority of these isolates showed a high level of resistance to tetracycline, cotrimoxazole, and penicillin, which makes treatment difficult. It is, therefore, necessary to collect data from various countries for the worldwide surveillance on emergence of macrolide resistance in *S. pneumoniae* isolates.
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Abbreviations: MIC, minimum inhibitory concentration; cMLS~B~, constitutive macrolide-lincosamide-streptograminB.
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Abbreviations: Tn, transposon; CSF, cerebrospinal fluid.
